TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Diagnostic yield for bleeding events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: minimum local anesthetic concentration (MLAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sedation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Hot Flash Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with an unacceptable adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Composite Error Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oppositional Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CPR Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity of lenalidomide monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ankle accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of patients discontinuing treatment before completing 12 months of therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time from treatment initiation to discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pathological Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bacterial Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAEs) of ≥Grade 3 Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants achieving PASI 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first treatment change
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to revision of the partial total knee prosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: urinary bladder displacement in millimeters during verbal instruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma Glucose Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease Activity Score Based on 28 Joints Count (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of follicle stimulating hormone (FSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Central line fall out rate
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Osimertinib
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Alveolo-arterial gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with treatment emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of binary restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: delinquency
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: violence
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Improvement of glycaemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose of intravenous sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Worst Itching Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Growth Rate Standard Deviation (SD) Score for Calendar Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Height SD Score for Calendar Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of analyte in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of analyte eliminated in urine from the time point t1 to time point t2 (Aet1-t2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to last unformed stool (TLUS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean time of survival post-treatment
Endpoint domain: Mortality/survival
Primary endpoint: Quality of life assessment: Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Influenza Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vaccination Coverage Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants developed iris posterior synechiae after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Head & Neck Lymphedema Occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute defibrillation thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: R1 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: score of bleeding symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Bleeding Rates (ABR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of target joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal end tidal concentration of sevoflurane/desflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in functional bowel symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Log10 Neutralization Index (LNI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Log10 Neutralizing Titer 50 (NT50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in post-bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: effective rate of pruritus relieving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of the Pain Intensity Differences (SPID) over 0-24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dentin density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Health-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: brain responses at rest and task-based (sensorimotor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain diffusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak GH Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Eating Attitudes Test (EAT-26)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eating & Meal Preparation Skills Questionnaire (EMPSA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Correlation with Spastic Paraplegia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation with Six-Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of SNAP questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of parents completing the survey
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IPF-related costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from Baseline liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline PRL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: proportion of mothers who took up Family Planning
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Plasma Dose-Proportionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue Dose-Proportionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMC Dose-Proportionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized 24 Hour Urinary Free Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to awake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Bioavailability of ALXN1210 SC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in allergen specific IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene and protein expression for autophagy and mitophagy biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Improvement (CGI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity of SL-RNA detection for relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of SL-RNA detection for cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalized Anxiety Disorder-7 (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of slides stained positive to PDL1 marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childhood Autism Rating Scale (CARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Bishops score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with positive tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of ERK and AKT in placenta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in normally aerated end-expiratory lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Grade 4 Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite endpoint (re-admission/ Emergency Department visit/ death)
Endpoint domain: Mortality/survival
Primary endpoint: Endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Motion of the esophageal tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absolute change in HbA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delivery week
Endpoint domain: Mortality/survival
Primary endpoint: Deterioration of Hearing Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Platelet engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With First Confirmed Cardiovascular Event of Major Adverse Cardiovascular Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of complete ST segment resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Markers of Autoimmunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants experiencing Treatment Related Adverse Events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing Treatment Related Serious Adverse Events (TRSAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in severity of VA symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric test measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Michigan Hand Outcomes Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quick DASH
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: changes in heart rate value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: oxygen saturation value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time length of grimacing and crying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Mean MMDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical Disease-Free Survival (bDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of second molar protraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucositis treatment effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for cervical dilatation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of cervical dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral neuropathic pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine aquaporin-2 concentration (u-AQP-2CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Output measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infection resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Differences in intestinal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Positive rate of 2019 Novel Coronavirus RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Postprandial Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Area Under the Curve (AUC) Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: confirmed (culture positive) infection
Endpoint domain: Adverse events/effects
Primary endpoint: Device Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Toxicities of neo-adjuvant chemoradiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Extent of interstitial edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TWSTRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI BOLD responses for Stop Signal Reaction Time Task (SSRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI BOLD responses for Go-NoGo Continuous Performance Task (CPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain structural connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in Monthly Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADHD-RS-IV Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with eRVR
Endpoint domain: Physiological/clinical
Primary endpoint: Taste evaluation using Bosutinib Taste Assessment Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Post-operative UTI
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Doses (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants free of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Prostaglandin E2 (PGE2) Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the plasma concentration versus time curve of Gleevec®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major pathological response rate (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of arteriovenous fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Participant Total Combined Symptom (TCS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Achieving PASI75 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Validity of amniotic fluid tandem mass spectrometry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change of time to reach T10 sensory spinal block level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in motor block level from PACU to discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline visual analog scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence Rate of ISTH Major Bleeding and CRNMB
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic Recurrent VTE Including VTE Related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of identifying the epileptogenic zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in moderate-intense physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in child's neurodevelopmental status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time required to initially position the assigned tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of Study related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of hysteroscopic compared to laparoscopic sterilization and IUD placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Change in Lumbar Spine Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Family quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Autism Diagnostic Observation Schedule, Second Edition (ADOS-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Autism Spectrum Quotient (AQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Dyadic Parent-Child Interaction Coding System (DPICS system)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: New ECC (presence/absence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum peak increase in SCr from baseline up to day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in Hemoglobin ≥1g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Visual Assessment of PD-L1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semiquantitative Assessment of Lung Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes